机译:11β-羟基类固醇脱氢酶1型调节糖皮质激素诱导的骨骼肌胰岛素抵抗。
Centre for Endocrinology, Diabetes and Metabolism, Institute of Biomedical Research, School of Clinical & Experimental Medicine, University of Birmingham, Birmingham, U.K.;
Centre for Endocrinology, Diabetes and Metabolism, Institute of Biomedical Research, School of Clinical & Experimental Medicine, University of Birmingham, Birmingham, U.K.;
Centre for Endocrinology, Diabetes and Metabolism, Institute of Biomedical Research, School of Clinical & Experimental Medicine, University of Birmingham, Birmingham, U.K.;
Centre for Endocrinology, Diabetes and Metabolism, Institute of Biomedical Research, School of Clinical & Experimental Medicine, University of Birmingham, Birmingham, U.K.;
AstraZeneca Diabetes & Obesity Drug Discovery, Mereside, Alderley Park, Macclesfield, Cheshire, U.K.;
Centre for Endocrinology, Diabetes and Metabolism, Institute of Biomedical Research, School of Clinical & Experimental Medicine, University of Birmingham, Birmingham, U.K.;
AstraZeneca Diabetes & Obesity Drug Discovery, Mereside, Alderley Park, Macclesfield, Cheshire, U.K.;
AstraZeneca Diabetes & Obesity Drug Discovery, Mereside, Alderley Park, Macclesfield, Cheshire, U.K.;
AstraZeneca Diabetes & Obesity Drug Discovery, Mereside, Alderley Park, Macclesfield, Cheshire, U.K.;
AstraZeneca Diabetes & Obesity Drug Discovery, Mereside, Alderley Park, Macclesfield, Cheshire, U.K.;
Department of Clinical Biochemistry, University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, U.K.;
Department of Clinical Biochemistry, University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, U.K.;
Centre for Endocrinology, Diabetes and Metabolism, Institute of Biomedical Research, School of Clinical & Experimental Medicine, University of Birmingham, Birmingham, U.K.;
AstraZeneca Diabetes & Obesity Drug Discovery, Mereside, Alderley Park, Macclesfield, Cheshire, U.K.;
Centre for Endocrinology, Diabetes and Metabolism, Institute of Biomedical Research, School of Clinical & Experimental Medicine, University of Birmingham, Birmingham, U.K.;
机译:11型11-羟基类固醇脱氢酶调节糖皮质激素诱导的骨骼肌胰岛素抵抗。
机译:11β-羟类脱氢酶1型shRNA改善糖皮质激素诱导的胰岛素抗性和小鼠腹部脂肪组织的脂解
机译:11β-羟类固醇脱氢酶1在人类皮脂腺中表达,并调节糖皮质激素诱导的脂质合成和SZ95皮细胞中toll样受体2的表达
机译:所选蛋白质表达的变化阐明骨骼肌型特异性对糖皮质激素诱导的肌肉恶病症的抗性
机译:Fnip1调节骨骼肌纤维类型规范,抗疲劳性和对肌营养不良症的敏感性。
机译:11β-羟基类固醇脱氢酶1型调节糖皮质激素诱导的骨骼肌胰岛素抵抗。
机译:11β-羟基类固醇脱氢酶1调节糖皮质激素诱导的骨骼肌胰岛素抵抗。